Outcome |
Relative effect (95% CI) |
Absolute effect (95% CI)1 |
Certainty of the Evidence (GRADE) |
Clinical improvement D28 |
RR: 1.05 (0.92 - 1.18) |
40 more per 1000 (from 63 fewer to 142 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
2 trials
Singh D, 2021; NCT04402866 2022
223 participants
|
|
Nezulcitinib (TD-0903) 830 per 1,000 (728 - 933) |
Placebo 791 per 1,000 |
|
Clinical improvement D60 |
Outcome not yet measured or reported
|
|
WHO progression score (level 7 or above) D28 |
RR: 0.51 (0.23 - 1.13) |
71 fewer per 1000 (from 112 fewer to 19 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
2 trials
Singh D, 2021; NCT04402866 2022
223 participants
|
|
Nezulcitinib (TD-0903) 74 per 1,000 (33 - 164) |
Placebo 145 per 1,000 |
|
WHO progression score (level 7 or above) D60 |
Outcome not yet measured or reported
|
|
All-cause mortality D28 |
RR: 0.41 (0.17 - 1.00) |
80 fewer per 1000 (from 113 fewer to 0 fewer)
|
Moderate certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Serious due to wide confidence interval consistent with the possibility for benefit and the possibility for no effect/trivial effect
|
2 trials
Singh D, 2021
223 participants
|
|
Nezulcitinib (TD-0903) 56 per 1,000 (23 - 136) |
Placebo 136 per 1,000 |
|
All-cause mortality D60 |
Outcome not yet measured or reported
|
|
Viral negative conversion D7 |
Outcome not yet measured or reported
|
|
Adverse events
|
RR: 0.34 (0.12 - 0.96) |
660 fewer per 1000 (from 880 fewer to 40 fewer)
|
Moderate certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Multicentre study conducted across several countries, therefore not downgraded for indirectness Imprecision: Serious due to wide confidence interval consistent with the possibility for benefit and the possibility for no effect/trivial effect
|
1 trials
Singh D, 2021
13 participants
|
|
Nezulcitinib (TD-0903) 340 per 1,000 (120 - 960) |
Placebo 1000 per 1,000 |
|
Serious adverse events
|
RR: 0.56 (0.28 - 1.12) |
76 fewer per 1000 (from 124 fewer to 21 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
2 trials
Singh D, 2021; NCT04402866 2022
223 participants
|
|
Nezulcitinib (TD-0903) 97 per 1,000 (48 - 193) |
Placebo 173 per 1,000 |
|
1The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect